Target intelligence / Profile preview

Serotonin transporter, Norepinephrine transporter, and Dopamine transporter (SERT, NET, DAT)

Target
SERT, NET, DAT
Molecular classification
Transporter, Neurotransmitter transporter, Solute carrier family protein (SLC6 family)
01

Overview

The serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT) are three closely related proteins belonging to the solute carrier family 6 (SLC6) of Na^+/Cl^−^-dependent neuronal membrane transporters. They mediate the rapid reuptake of their respective monoamine neurotransmitters—serotonin (5-HT), norepinephrine (NE), and dopamine (DA)—from the synaptic cleft back into presynaptic neurons, thereby terminating neurotransmission and recycling neurotransmitter for vesicular storage or degradation. These transporters are expressed throughout the central and peripheral nervous systems and play vital roles in mood regulation, cognitive function, and motor control. They are considered primary pharmacological targets for antidepressants, psychostimulants, and drugs of abuse, and their dysfunction is implicated in a range of neuropsychiatric and neurodegenerative diseases.

Other names
Serotonin transporter (also: 5-HT transporter, 5-HTT; gene: SLC6A4)Norepinephrine transporter (also: noradrenaline transporter, NET; gene: SLC6A2)Dopamine transporter (also: DAT; gene: SLC6A3)Collectively: monoamine transporters, Na^+/Cl^−^-dependent monoamine transporters
02

Mechanism of action

Competitive inhibition or blockade of neurotransmitter reuptake (SSRIs, SNRIs, TCAs, cocaine, methylphenidate) Substrate reversal or release (amphetamines, MDMA) Modulation of transporter trafficking and phosphorylation

03

Biological functions

Reuptake of neurotransmitters from synaptic cleft (serotonin, norepinephrine, dopamine)Regulation of monoaminergic neurotransmissionModulation of synaptic signal amplitude and durationHomeostasis of neurotransmitter levels in CNS and peripheral tissues
04

Disease associations

Neuropsychiatric disorders (e.g., depression, anxiety, ADHD, schizophrenia, bipolar disorder)Substance use disorders (cocaine, amphetamine, MDMA, methamphetamine abuse)Neurodegenerative diseases (e.g., dopamine transporter deficiency syndrome, Parkinsonian syndromes)Other (eating disorders, cardiovascular regulation, possibly autism spectrum disorder)
05

Safety considerations

Addiction and abuse potential for drugs affecting these transporters (psychostimulants, cocaine, amphetamines)Serotonin syndrome (overactivation of SERT)Cardiovascular risks (due to peripheral NET inhibition)Neurotoxicity and psychiatric side effects with transporter blockers/releasersWithdrawal, tolerance, dependence
06

Interacting drugs

Selective serotonin reuptake inhibitors (SSRIs) — mainly target SERT (e.g., fluoxetine, sertraline, citalopram)

7 more in the full profile.

07

Biomarkers

Transporter binding or occupancy measured by PET/SPECT ligands for SERT, NET, and DATSLC6 gene polymorphisms (e.g., SLC6A3 VNTR for DAT, SLC6A4 promoter variants for SERT)Platelet SERT expression and activity (peripheral marker)Dopamine transporter imaging (DaTscan) for neurodegenerative disorders

Beyond the preview

Go deeper on Serotonin transporter, Norepinephrine transporter, and Dopamine transporter (SERT, NET, DAT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serotonin transporter, Norepinephrine transporter, and Dopamine transporter (SERT, NET, DAT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call